Hrckulak Dusan, Onhajzer Jakub, Krausova Michaela, Stastna Monika, Kriz Vitezslav, Janeckova Lucie, Korinek Vladimir
Laboratory of Cell and Developmental Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague 4, Czech Republic.
Institute of Pathology 1St Faculty of Medicine Charles University and General University Hospital, Prague, Czech Republic.
Transgenic Res. 2025 Jan 9;34(1):9. doi: 10.1007/s11248-024-00429-2.
Proto-oncogene KRAS, GTPase (KRAS) is one of the most intensively studied oncogenes in cancer research. Although several mouse models allow for regulated expression of mutant KRAS, selective isolation and analysis of transforming or tumor cells that produce the KRAS oncogene remains a challenge. In our study, we present a knock-in model of oncogenic variant KRAS that enables the "activation" of KRAS expression together with production of red fluorescent protein tdTomato. Both proteins are expressed from the endogenous Kras locus after recombination of a transcriptional stop box in the genomic DNA by the enzyme flippase (Flp). We have demonstrated the functionality of the allele termed RedRas (abbreviated Kras) under in vitro conditions with mouse embryonic fibroblasts and organoids and in vivo in the lung and colon epithelium. After recombination with adenoviral vectors carrying the Flp gene, the Kras allele itself triggers formation of lung adenomas. In the colon epithelium, it causes the progression of adenomas that are triggered by the loss of tumor suppressor adenomatous polyposis coli (APC). Importantly, cells in which recombination has successfully occurred can be visualized and isolated using the fluorescence emitted by tdTomato. Furthermore, we show that KRAS production enables intestinal organoid growth independent of epidermal growth factor (EGF) signaling and that the KRAS function is effectively suppressed by specific inhibitor MRTX1133.
原癌基因KRAS,一种GTP酶(KRAS),是癌症研究中研究最为深入的癌基因之一。尽管有几种小鼠模型可以调节突变型KRAS的表达,但选择性分离和分析产生KRAS癌基因的转化细胞或肿瘤细胞仍然是一项挑战。在我们的研究中,我们提出了一种致癌变体KRAS的敲入模型,该模型能够在产生红色荧光蛋白tdTomato的同时“激活”KRAS表达。在基因组DNA中的转录终止盒通过翻转酶(Flp)重组后,这两种蛋白质均从内源性Kras基因座表达。我们已经在体外条件下,利用小鼠胚胎成纤维细胞和类器官,以及在体内的肺和结肠上皮中,证明了名为RedRas(缩写为Kras)的等位基因的功能。在用携带Flp基因的腺病毒载体进行重组后,Kras等位基因本身会引发肺腺瘤的形成。在结肠上皮中,它会导致由肿瘤抑制因子腺瘤性息肉病(APC)缺失引发的腺瘤进展。重要的是,重组成功发生的细胞可以利用tdTomato发出的荧光进行可视化和分离。此外,我们表明KRAS的产生能够使肠道类器官独立于表皮生长因子(EGF)信号生长,并且KRAS功能可以被特异性抑制剂MRTX1133有效抑制。